Table 1 Demographic, clinical, laboratory, treatment characteristics in the study of SLE patients (n = 50)
Characteristic | SLE patients (n = 50) |
|---|---|
Demographic and clinical characteristics | |
Age (years), M ± SD | 26.98 ± 8.95 |
Sex, n (%) | |
Female | 50 (100) |
Residence, n (%) | |
Urban | 26 (52) |
Rural | 24 (48) |
SLE disease duration (months), median (min–max) | 18 (0–108) |
Lupus-related manifestations, n (%) | |
Cutaneous manifestations | 26 (52) |
Vasculitis | 2 (4) |
Nephritis | 19 (38) |
Arthritis | 20 (40) |
Serositis | 8 (16) |
Hematological abnormalities | 25 (50) |
Laboratory characteristics, n (%) | |
Thrombocytopenia | 5 (10) |
Leucopenia | 5 (10) |
Urinary casts | 5 (10) |
Hematuria | 14 (28) |
Proteinuria | 22 (44) |
Pyuria | 19 (38) |
Serological markers for SLE | |
Positive ANA, n (%) | 50 (100) |
Positive anti-dsDNA, n (%) | 16 (32) |
SLEDAI score, median (min–max) | 14 (1–20) |
Immunosuppressive medications used for treatment, n (%) | |
Steroids | 50 (100) |
IV pulse methylprednisolone high dose | 15 (30) |
Moderate dose | 7 (14) |
Low dose | 18 (36) |
Hydroxychloroquine | 10 (20) |
Azathioprine | 28 (56) |
Mycophenolate mofetil | 35 (70) |
Cyclophosphamide | 10 (20) |